Genetic Signatures Ltd. · ASX:GSS
Genetic Signatures — Shareholder Meeting (November 2017)
22 slides from Genetic Signatures's shareholder meeting presentation, Nov 28, 2017
Slide 1: AGM Presentation November 2017
ASX: GSS AGM PRESENTATION NOVEMBER 2017 Genetic Signatures Limited Investor Presentation – November 2017
Slide 2: Investment highlights
Investment highlights A REVENUE-STAGE HEALTHCARE COMPANY ACCELERATING THE GLOBAL COMMERCIALISATION OF ITS UNIQUE DIAGNOSTIC PRODUCTS ― Genetic Signatures (GSS) designs and manufactures Molecular Diagnostic products that have substantially greater efficacy than traditional solutions ― Domestic custom
Slide 3: GSS snapshot
GSS snapshot All GSS products underpinned by proprietary 3base™ technology to Proprietary enable customers to identify a wider array of infections than standard tests technology 3base™ unique approach optimises DNA analysis by simplifying the natural sequences resulting in faster and more accurate r
Slide 4: Significant operational progress since IPO in 2015
Significant operational progress since IPO in 2015 Corporate Apr-15 Nov-15 Jun-16 Mar-17 First installation of 3baseTM Collaboration Launch ASR Launch and first respiratory virus kits with UCLA products in the sales of STI announced USA Genital Pathogen Aug-15 Detection Kit Mar-15 Distribution Sep-1
Slide 5: 1Q FY18 trading update
1Q FY18 trading update STRONG REVENUE GROWTH CONTINUES WITH SOME SEASONALITY 1Q FY18 Revenue Update Quarterly revenue (A$000) 754 Record quarterly revenues achieved in Q1 FY18 of A$754k 575 Some seasonality in 540 revenue due to strong 495 463 460 demand for respiratory kits 442 423 410 across t
Slide 6: 3base enables a step-change in MDx efficacy
3baseTM enables a step-change in MDx efficacy GSS owns the proprietary 3base™ technology Unique and innovative approach simplifies the DNA and RNA sequences of bacterial, viral, protozoan and fungal pathogens The resultant simplified genetic sequences enables a step-change in efficacy in molecul
Slide 7: EasyScreen products built on 3base technology
EasyScreenTM products built on 3baseTM technology GSS is commercialising a range of MDx tests based on 3baseTM and branded EasyScreenTM EasyScreenTM kits offer faster and more effective detection of infectious disease Three product families available Platform agnostic – compatible with common co
Slide 8: 3base offers significant benefits to all parties
3baseTM offers significant benefits to all parties Saves lives Saves costs More accurate test results More results per patient Faster turnaround specimen Hospital & 4-5 hours (vs 4-5 days) Patient pathology Easy to use common workflow between tests Improved efficacy & groups breadth of det
Slide 9: Powerful evidence of efficacy from clinical trials
Powerful evidence of efficacy from clinical trials Clinical trials demonstrate efficacy St Vincent’s Hospital Evaluation Study results Evaluation study conducted at St Vincent’s Pathogen Conventional EasyScreen™ Hospital, Sydney in 2014 Methods* Campylobacter 7 9 221 patient samples tested and compa
Slide 10: 7 products underpinned by 3base technology
7 products underpinned by 3baseTM technology Product group Target pathogens Key highlights EasyScreen™ 20+ enteric pathogens All tests have full regulatory approval in Three Enteric Includes Salmonella, C. difficile Bacteria, Europe (10-20x the size of Aus market) existing Protozoan and Viral Detect
Slide 11: Clear path to global commercialisation for all products
Clear path to global commercialisation for all products Australia EU US Product Trials Pilot stage Approvals Ready for Approvals Ready for FDA trials Approval Products development underway revenue2 and sales trials and sales ASR trials underway and sales Existing EasyScreen™ 2018 2019 products Enter
Slide 12: EasyScreen customers are strong advocates
EasyScreenTM customers are strong advocates “We use EasyScreenTM at ACL for its robust user Tony Field friendly automation, higher levels of specificity for Operations Manager clinical samples and our confidence in delivering Australian Clinical Labs clinically significant results to our clinicians.
Slide 13: GSS has multiple levers to grow revenues
GSS has multiple levers to grow revenues New customer growth Illustrative GSS revenue trajectory Continue to acquire new customers in Australia European sales recently enabled by key regulatory CE-IVD approvals High velocity, In US, multiple products now seeking compounding regulatory approval
Slide 14: Executing a global strategy for commercialisation
Executing a global strategy for commercialisation 12+ TRIALS PLANNED GLOBALLY INCLUDING 3 DOMESTIC TRIALS 2 Europe: Building out distributor model Trials underway Distributors appointed (Italy, Israel, Ireland and Poland) CE-IVD approvals granted (4 products) Direct Sales and Support Staff est
Slide 15: Australia: continue rapid growth
1 Australia: continue rapid growth AUSTRALIA IS THE PLATFORM FOR INTERNATIONAL SALES Commercialisation progress Next steps Established foothold Rapid customer acquisitions ― Secured relationships with top tier ― New Australian Sales Marketing and Support customers in NSW and Victoria manager appoint
Slide 16: Europe: building out distributor model
2 Europe: building out distributor model STRONG PROGRESS ON MULTIPLE FRONTS TO ACCESS VALUABLE MARKET Commercialisation progress Next steps Distributors hired and testing underway Strategic market with large opportunity ― Full distributors appointed in Italy, Ireland, ― Europe has an addressable MDx
Slide 17: North America: accelerate direct sales approach
3 North America: accelerate direct sales approach SALES STRATEGY TO ACCELERATE FOLLOWING FDA APPROVAL Commercialisation progress Next steps Foothold established Largest market for MDx globally ― Hired US Sales Director in November 2016 ― Addressable market of approximately US$1,265m, c.55% of the gl
Slide 18: Financial performance
Financial performance Year ending Year ending Other income includes R&D rebates A$000 30 June 2016 30 June 2017 received (A$1.5m in FY2017) and interest Sales revenue 1,825 2,038 received Other income 1,533 1,757 Total revenue 3,358 3,795 Primarily staff salaries Cost of goods sold (462) (602)
Slide 19: Near term focus on product range and sales growth
Near terms focus on product range and sales growth ― Commercial release of Flavivirus and ESBL/CPO PRODUCTS kits initially in Australia New releases ― Regulatory registrations for STI and respiratory kits AU Sales ― Strong focus of securing new customers New customers ― Additional hospital and patho
Slide 20: Board of Directors
Board of Directors WELL CREDENTIALED BOARD WITH SUCCESS IN COMMERCIALISATION Management team with a proven track record in molecular diagnostics industry and extensive experience in bringing products from clinical development to commercialisation • Significant experience in leading international sal
Slide 21: Appendix – the science behind 3base technology
Appendix – the science behind 3baseTM technology 3baseTM technology in summary 3baseTM technology in the detection process ― 3baseTM platform technology converts original 4- base microbial genome to 3-base, Regular cell Lysis and ― Reducing complexity in molecular testing preparation steps ― Convers
Slide 22: Disclaimer
Disclaimer This presentation was prepared by Genetic Signatures Limited known as “Genetic Signatures“, (“GSS” or “the Company”), in order to discuss its business with various interested parties. This presentation in its entirety has been released to the market via the Australian Securities Exchange
Genetic Signatures — Shareholder Meeting (November 2017) on 6ix